Literature DB >> 3045112

Pharmacology of sertraline: a review.

J Heym1, B K Koe.   

Abstract

Sertraline is a member of a new class of psychotherapeutic agents that selectively inhibit serotonin reuptake in the brain. Animal studies have demonstrated that inhibition of serotonin reuptake leads to enhanced serotonergic neurotransmission and indirectly results in a down-regulation of beta-adrenoceptors. The preclinical pharmacology of sertraline predicts antidepressant activity without accompanying anticholinergic, cardiotonic, or sedative side effects. Recent laboratory and clinical observations pertaining to body weight and obsessive compulsive disorder suggest the possibility of broader clinical indications for selective serotonin reuptake blockers such as sertraline.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3045112

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  14 in total

1.  Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes.

Authors:  Z H Xu; W Wang; X J Zhao; S L Huang; B Zhu; N He; Y Shu; Z Q Liu; H H Zhou
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

2.  Changes in temporal attention inhibition following prolonged exposure and sertraline in the treatment of PTSD.

Authors:  Aileen Echiverri-Cohen; Lori A Zoellner; Robert Gallop; Norah Feeny; Jeffrey Jaeger; Michele Bedard-Gilligan
Journal:  J Consult Clin Psychol       Date:  2016-02-22

3.  Sertraline in the treatment of premature ejaculation: a double-blind placebo controlled study.

Authors:  H Biri; K Isen; Z Sinik; M Onaran; B Küpeli; I Bozkirli
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

4.  Sertraline and cocaine-induced locomotion in mice. I. Acute studies.

Authors:  M E Reith; H L Wiener; C T Fischette
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

5.  Sertraline and cocaine-induced locomotion in mice. II. Chronic studies.

Authors:  M E Reith; C T Fischette
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 6.  Sertraline versus other antidepressive agents for depression.

Authors:  Andrea Cipriani; Teresa La Ferla; Toshi A Furukawa; Alessandra Signoretti; Atsuo Nakagawa; Rachel Churchill; Hugh McGuire; Corrado Barbui
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

7.  Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers.

Authors:  R A Ronfeld; L M Tremaine; K D Wilner
Journal:  Clin Pharmacokinet       Date:  1997       Impact factor: 6.447

Review 8.  The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders.

Authors:  G MacQueen; L Born; M Steiner
Journal:  CNS Drug Rev       Date:  2001

9.  Effect of sertraline on breathing in depressed patients without moderate-to-severe sleep-related breathing disorders.

Authors:  Bin Zhang; Yanli Hao; Fujun Jia; Xueli Li; Yi Tang; Huirong Zheng; Wuhan Liu
Journal:  Sleep Breath       Date:  2015-03-11       Impact factor: 2.816

Review 10.  Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder.

Authors:  D Murdoch; D McTavish
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.